The 2019 edition of the International Neurotoxin Association Conference (Toxins 2019) was recently held in Copenhagen, Denmark and was extremely well attended and received with more than 1,400 participants from 61 countries. The scientific programme featured top speakers, stimulating discussions, and scientific breakthroughs. The articles presented in this conference report provide a very good overview of the plenaries and workshops and cover major innovative developments in basic sciences, clinical research, and treatment applications in the field of botulinum toxins. More specifically, the topics presented in this report include the well established use of botulinum toxins in spasticity and cervical dystonia with emphasis on recent clinical trials and treatment algorithms, the more recently established efficacy of botulinum toxin A in chronic migraine, but also new promising applications in peripheral neuropathic pain and in Parkinson disease with regards to tremor and sialorrhea. Novel versions of botulinum toxins are also largely covered.
I am confident that these various and balanced presentations illustrate the high quality and dynamism of preclinical and clinical research in the field of botulinum toxins and will be of great interest to all medical doctors and researchers interested in botulinum toxins and their applications.
Nadine Attal, MD, PhD, is Professor of Therapeutics and Pain in University Versailles Saint Quentin, France and responsible for the Center of Evaluation and Treatment of Pain in Ambroise Paré Hospital, Boulogne-Billancourt. She is also a member of the INSERM U-987 Research Unit on Pain directed by Didier Bouhassira. Her research activity mainly focuses on neuropathic pain and pain management. She has coordinated several international guidelines on neuropathic pain and authored more than 140 peer-reviewed papers in high impact factor journals (H index 50). She is a Council member of the International Association for the Study of Pain and of the the French Society of Pain and member of the scientific committee of the European Academy of Neurology. She has been appointed knight (« Chevalier de la légion d’honneur ») in 2016.
Conflict of Interest Statement : Nadine Attal has disclosures with Sanofi Pasteur MSD, MSD, Grunenthal, Aptynix, and Ipsen, unrelated to this conference, in the past 36 months (scientific advice or speakers bureau).
Article image: Medicom
The content and interpretation of these conference highlights are the views and comments of the speakers/authors.